Defence Therapeutics Inc Class A · CSE:DTC
Defence Therapeutics Inc Class A — Investor Presentation (October 2026)
20 slides from Defence Therapeutics Inc Class A's investor presentation, October 2026
Slide 1: Defence Therapeutics: Unlocking the Power of Cancer Drugs
I N VE ST OR P R ES EN TA TI ON · OC TO BE R 20 2 6 Defence Therapeutics Unlocking the Power of Cancer Drugs CSE: DTC · OTCQB: DTCFF · FSE: DTC · Montreal, Canada
Slide 2: Forward-Looking Statements
I MP O R T A NT N O T I CE Forward-Looking Statements This presentation contains forward-looking information within the meaning of applicable Canadian securities laws, including statements about Defence Therapeutics Inc.’s (“Defence” or the “Company”) business and corporate strategy, its Accum®, ADC
Slide 3: Defence Therapeutics at a Glance
C OMPA N Y SN A PS HOT Defence Therapeutics at a Glance LISTINGS CSE: DTC · OTCQB: DTCFF · FSE: DTC MA RKE T S NAPS H O T LOCATIONS Montreal, Quebec, Canada $37.3M CAD Market capitalization (approx., Sept 2026) Hamilton, Ontario, Canada FOCU S Precision oncology via The Accum® Platform 75.8M Common
Slide 4: Powerful Oncology Therapies. Persistent Biological Barriers.
T HE PROBL E M Powerful Oncology Therapies. Persistent Biological Barriers. Checkpoint Inhibitors | Targeted Radiopharmaceuticals | Antibody -Drug Conjugates P OW E RFUL THE RAP I E S BI OL OG IC AL BARR IE RS Checkpoint inhibitors (CPIs), antibody-drug conjugates CPIs — insufficient immune recognit
Slide 5: The Accum Platform: Unlocking the Full Potential of Oncology's Most Powerful Therapies
T HE SO L UT I O N The Accum® Platform: Unlocking the Full Potential of Oncology’s Most powerful Therapies The Accum® Platform combines two nature-inspired mechanisms—endosomal escape and nuclear localization—to overcome intracellular barriers that can limit therapeutic performance. BROADLY APPLICAB
Slide 6: One Platform. Multiple Paths to Value. Execution Underway.
W H Y D E F E N C E T H E R AP U T I C S , W H Y N O W One Platform. Multiple Paths to Value. Execution Underway. Differentiated Oncology Platform High-Value Commercial Opportunities • Accum® is designed to enhance established and next-generation • AccuTOX® — clinical-stage immuno-oncology opportuni
Slide 7: One Platform. Multiple Paths to Value.
M U L T I P L E P AT H S T O V AL U E One Platform. Multiple Paths to Value. Focused investment across three pillars where Accum® can create differentiated clinical and commercial value 01 Positioning AccuTOX® for Clinical Development and Value Creation. 02 Building a Proprietary Pipeline of Accum®-
Slide 8: Making Tumors More Visible to the Immune System
P I LL A R 1 O F 3 Making Tumors More Visible to the Immune System AccuTOX® combines direct tumor killing with enhanced antigen presentation to amplify checkpoint inhibitor activity ~2x ~85% 100% Increase in MHC-I antigen presentation on Slower tumour growth with combination Survival across all trea
Slide 9: Positioning AccuTOX for Clinical Development and Value Creation
P I LL A R 1 O F 3 Positioning AccuTOX® for Clinical Development and Value Creation Clinical-stage asset with regulatory clearance and trial infrastructure in place OUR MOST CLI NICAL LY ADVA NCED A SSE T MA R KE T O PP OR T UNI T Y Regulatory path established Health Canada and FDA clearance to init
Slide 10: Building a Proprietary Pipeline of Accum-Enabled Radiopharmaceuticals
P I LL A R 2 O F 3 Building a Proprietary Pipeline of Accum®-Enabled Radiopharmaceuticals New Lead er ship Targeted radiopharmaceuticals are emerging as a new class of cancer Dr. Ryan Simms therapy but constrained by limited tumour uptake and retention. COO & Head of Radiopharmaceutical Programs WHY
Slide 11: Expanding Accum into High-Value Radiopharmaceuticals
P I LL A R 2 O F 3 Expanding Accum® into High-Value Radiopharmaceuticals S TRATEGI C LO C ATI ON MAR KET VAL I DATE D WI TH REC ENT M&A DEA LS Positioned in a Leading Radiopharmaceutical Hub Lantheus × Evergreen Theragnostics ~$1.0B PET diagnostic OCTEVY; preclinical and clinical programs April 2025
Slide 12: Accum Enhances HER2 ADCs Across Multiple Breast Cancer Models
P I LL A R 3 O F 3 Accum® Enhances HER2 ADCs Across Multiple Breast Cancer Models ~20x Greater anti-tumour efficacy in vivo models 2 Marketed ADCs Enhancement demonstrated with both T-DM1 Difficult-to-treat models Activity demonstrated in resistant and lower- with Accum®-T-DM1® vs. T-DM1 alone and T
Slide 13: Drive Accum Adoption Through Partnerships & Scalable Licensing Model
P I LL A R 3 O F 3 Drive Accum® Adoption Through Partnerships & Scalable Licensing Model MAR KET VAL I DATE D WI TH MUL TI PL E R ECEN T WE ENABLE, NOT COMPETE L I CEN CI NG D EAL S Our objective is not to develop competing ADCs, but to enable ADC developers — engaging companies whose assets could b
Slide 14: Partnership-Led Licensing Model
B U S I N E S S M O D EL Partnership-Led Licensing Model 1 2 3 4 Partner Brings › Defence Applies › Licensing Revenue › Reinvest in the the Asset Accum® Pipeline An ADC or biologic developer Accum® is evaluated to enhance Defence earns upfront Proceeds fund AccuTOX®, contributes a clinical or intrac
Slide 15: An Experienced Team Leading the Next Stage of Company Growth
L E AD ER S H I P An Experienced Team Leading the Next Stage of Company Growth Dr. Amie Phinney, PhD, MBA Sébastien Plouffe President & Chief Executive Officer, Board Director Executive Chairman & Founder, Board Director 20+ years in international biotech leadership, including Founded Defence and bu
Slide 16: An Expanded Board Adds Deep Scientific and Business Experience
GO V E R NA N CE An Expanded Board Adds Deep Scientific and Business Experience New! New! Dr. John Lambert Sherry Aulin Board Director — ADC Pioneer Board Director — Finance Expert 40+ years in ADC science. Former Chief Scientific Officer and EVP of Research at Accomplished C-suite executive with a
Slide 17: A Scientific Advisory Board with Broad Scientific Expertise
GO V E R NA N CE A Scientific Advisory Board with Broad Scientific Expertise Rob Leanna Danny Chui Dr. Sarkis Meterissian Dr. Svetlana Selivanova ADC & Biologics Manufacturing Antibody & ADC Engineer Oncology researcher & physician Radiotherapeutics Expert 17 D E F E NC E T H E R A P E UT I C S · C
Slide 18: What to Expect Over the Next Twelve Months
ROADMAP What to Expect Over the Next Twelve Months Defined milestones across each strategic pillar ACCUTOX® RADIOTHERAPEUTICS ADC PARTNERSHIPS Define the highest-value Generate foundational Accum® data Expand Accum®-ADC profiling commercialization path with partners Update clinical development plan
Slide 19: Investment Highlights
S UMMA RY Investment Highlights Differentiated, IP-protected platform Capital-efficient commercialization strategy 8 U.S. granted patents and preclinical data demonstrating Partner-led ADC business model designed to generate near-term enhancement of multiple biologic drug categories revenue, with mi
Slide 20: Thank You for Your Continued Confidence.
L O O K I NG A HE A D Thank You for Your Continued Confidence. “With a differentiated technology platform and a focused strategy, Defence is well positioned to translate years of scientific innovation into programs and partnerships that can define our future.” — Dr. Amie Phinney, PhD, MBA, President
Defence Therapeutics — Investor Presentation (October 2026) on 6ix